ATE432085T1 - Stimulationsfaktor für dendriten - Google Patents

Stimulationsfaktor für dendriten

Info

Publication number: ATE432085T1
Authority: AT; Austria
Prior art keywords: dendrites; dendritic cells; cells; stimulation factor; flt3
Prior art date: 1995-10-04

Application number

AT96936216T

Other languages

English (en)

Inventor

Kenneth Brasel

Stewart Lyman

Eugene Maraskovsky

Hilary R Mckenna

David Lynch

Original Assignee

Immunex Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-10-04

Filing date

1996-10-03

Publication date

2009-06-15

1996-10-03 Application filed by Immunex Corp filed Critical Immunex Corp

2009-06-15 Application granted granted Critical

2009-06-15 Publication of ATE432085T1 publication Critical patent/ATE432085T1/de

Links

210000001787 dendrite Anatomy 0.000 title 1
230000000638 stimulation Effects 0.000 title 1
210000004443 dendritic cell Anatomy 0.000 abstract 3
102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 abstract 2
101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 1
210000001744 T-lymphocyte Anatomy 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
210000003958 hematopoietic stem cell Anatomy 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
210000000130 stem cell Anatomy 0.000 abstract 1
239000012646 vaccine adjuvant Substances 0.000 abstract 1
229940124931 vaccine adjuvant Drugs 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Epidemiology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Hematology (AREA)
Cell Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Virology (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Mycology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT96936216T 1995-10-04 1996-10-03 Stimulationsfaktor für dendriten ATE432085T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US53914295A	1995-10-04	1995-10-04
PCT/US1996/015990 WO1997012633A1 (en)	1995-10-04	1996-10-03	Dendritic cell stimulatory factor

Publications (1)

Publication Number	Publication Date
ATE432085T1 true ATE432085T1 (de)	2009-06-15

Family

ID=24149974

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96936216T ATE432085T1 (de)	1995-10-04	1996-10-03	Stimulationsfaktor für dendriten

Country Status (23)

Country	Link
EP (1)	EP0871487B1 (de)
JP (1)	JP3631496B2 (de)
KR (2)	KR100676792B1 (de)
CN (1)	CN1172718C (de)
AT (1)	ATE432085T1 (de)
AU (1)	AU697539B2 (de)
BR (1)	BR9610802A (de)
CA (1)	CA2232865A1 (de)
CZ (1)	CZ97798A3 (de)
DE (1)	DE69637942D1 (de)
EA (1)	EA199800272A1 (de)
EE (1)	EE9800105A (de)
ES (1)	ES2323818T3 (de)
IS (1)	IS4703A (de)
LV (1)	LV12085B (de)
NO (1)	NO981374L (de)
NZ (1)	NZ321039A (de)
PL (1)	PL187329B1 (de)
RO (1)	RO120579B1 (de)
SI (1)	SI9620116A (de)
SK (1)	SK40898A3 (de)
TR (1)	TR199800607T1 (de)
WO (1)	WO1997012633A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6429199B1 (en)	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030026782A1 (en)	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US9068164B1 (en) *	1995-02-02	2015-06-30	Tristem Trading (Cyprus) Limited	Method of preparing an undifferentiated cell
JP2002514047A (ja) *	1996-07-10	2002-05-14	イミュネックス・コーポレーション	樹状細胞を活性化する方法
AUPO388396A0 (en) *	1996-11-27	1996-12-19	Ludwig Institute For Cancer Research	Cellular adjuvant
WO1998057655A1 (en) *	1997-06-17	1998-12-23	Immunex Corporation	A method of enhancing antigen-specific peripheral immune tolerance
FR2775692B1 (fr) *	1998-03-03	2000-06-16	Roussy Inst Gustave	Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
US6849452B1 (en)	1998-03-03	2005-02-01	Institut Gustave Roussy	Methods for activating natural killer (NK) cells and means for carrying out said methods
FR2782524B1 (fr) *	1998-08-21	2002-07-19	Roussy Inst Gustave	Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
IL139813A0 (en)	1998-05-22	2002-02-10	Loeb Health Res Inst At The Ot	Methods and products for inducing mucosal immunity
WO1999062537A1 (en) *	1998-06-04	1999-12-09	The Rockefeller University	Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins
US6291661B1 (en)	1998-07-02	2001-09-18	Immunex Corporation	flt3-L mutants and method of use
WO2000012122A2 (de) *	1998-08-27	2000-03-09	Universitätsklinikum Freiburg	Niedermolekulare fragmente der hyaluronsäure zur herstellung von impfstoffen
GB9827604D0 (en) *	1998-12-15	1999-02-10	Lorantis Ltd	Methods of immunosuppression
WO2001009303A2 (en) *	1999-07-30	2001-02-08	Vical Inc.	Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER
JP2004522403A (ja) *	1999-11-03	2004-07-29	パウダージェクトヴァクシンズ，インコーポレイテッド	抗原発現を駆動する哺乳動物ｃｄ８０／ｃｄ８６遺伝子プロモーターを有する核酸ワクチン組成物
US7541184B2 (en)	2000-02-24	2009-06-02	Invitrogen Corporation	Activation and expansion of cells
JP2003523398A (ja) *	2000-02-24	2003-08-05	ザボードオブトラスティーズオブザリーランドスタンフォードジュニアユニバーシティ	樹状細胞のインビボ活性化によるアジュバント治療
US7572631B2 (en)	2000-02-24	2009-08-11	Invitrogen Corporation	Activation and expansion of T cells
CA2407336A1 (en) *	2000-04-25	2001-11-01	Immunex Corporation	Method for treatment of tumors using photodynamic therapy
WO2002036141A2 (en) *	2000-11-02	2002-05-10	Immunex Corporation	Method of enhancing lymphocyte-mediated immune responses
AU2002225927A1 (en) *	2000-11-17	2002-05-27	Immunex Corporation	Chemoattractant recruitment of dendritic cells for enhancement of immunization
PT1441591T (pt) *	2001-09-06	2016-10-06	Northwest Biotherapeutics Inc	Composições e métodos para ativaçao linfocitária de células dendríticas monocíticas e células para resposta th-1
KR100490308B1 (ko) *	2002-02-25	2005-05-17	크레아젠 주식회사	면역 치료용 성숙화된 수지상 세포 백신의 제조방법
PL377028A1 (pl) *	2002-03-26	2006-01-23	Immunex Corporation	Sposoby wykorzystania ligandu Flt-3 w procedurach immunizacyjnych
US20050084967A1 (en)	2002-06-28	2005-04-21	Xcyte Therapies, Inc.	Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
KR100522526B1 (ko) *	2002-11-28	2005-10-19	주식회사 바이넥스	면역 치료용 수지상 세포의 제조방법
KR100614220B1 (ko) *	2004-11-08	2006-08-21	고려대학교 산학협력단	Ｆｌｔ3 리간드 유전자를 발현하는 살모넬라 균주 및 이를함유하는 항암 치료용 조성물
DE102005016234B4 (de) *	2005-04-08	2008-05-15	Tgc Biomics Gmbh	Verfahren zur Einschleusung von exogenem Antigen in den MHC I-Präsentationsweg von Zellen
KR100818215B1 (ko)	2006-10-11	2008-04-01	재단법인서울대학교산학협력재단	Ｃｄ３４양성 줄기세포로부터 ｔ 임파구 전구체를 제조하는 방법
KR101264811B1 (ko)	2011-05-20	2013-05-15	충남대학교산학협력단	마이코박테리움 압세수스의 ＭＡＢ０９８１ｃ 단백질을 이용한 수지상 세포의 성숙방법
AU2017294751B2 (en)	2016-07-13	2023-10-05	Ohio State Innovation Foundation	Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity
AU2019404098A1 (en)	2018-12-18	2021-05-27	Boehringer Ingelheim Io Canada Inc.	FLT3 agonist antibodies and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US826250A (en)	1905-12-20	1906-07-17	Albert Huck	Switch for toy railways.
US4714680B1 (en)	1984-02-06	1995-06-27	Univ Johns Hopkins	Human stem cells
US5391485A (en)	1985-08-06	1995-02-21	Immunex Corporation	DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
EP0790307A1 (de)	1986-12-16	1997-08-20	Gist-Brocades B.V.	Molekulare Klonierung und Expression von menschlichem IL-3
OA09736A (en)	1987-02-18	1993-11-30	Schering Biotech Corp	"Human interleukin-3 and muteins thereof".
JPH03502322A (ja)	1987-10-30	1991-05-30	イミュネックス・コーポレーション	ヒトコロニー形成刺激因子の非グリコシル化類似体
US5108910A (en)	1989-08-22	1992-04-28	Immunex Corporation	DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
US5073627A (en)	1989-08-22	1991-12-17	Immunex Corporation	Fusion proteins comprising GM-CSF and IL-3
EP1241258A3 (de)	1989-10-16	2003-12-10	Amgen Inc.	Stamzellfaktor
US5199942A (en)	1991-06-07	1993-04-06	Immunex Corporation	Method for improving autologous transplantation
CA2122141C (en)	1991-10-23	2007-07-17	Shelly Heimfeld	Methods for selectively expanding stem cells
NZ314644A (en) *	1993-05-24	2000-11-24	Immunex Corp	Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue
US5554512A (en)	1993-05-24	1996-09-10	Immunex Corporation	Ligands for flt3 receptors
US5405772A (en) *	1993-06-18	1995-04-11	Amgen Inc.	Medium for long-term proliferation and development of cells

1996
- 1996-10-03 SK SK408-98A patent/SK40898A3/sk unknown
- 1996-10-03 EA EA199800272A patent/EA199800272A1/ru unknown
- 1996-10-03 WO PCT/US1996/015990 patent/WO1997012633A1/en not_active Ceased
- 1996-10-03 CN CNB96197351XA patent/CN1172718C/zh not_active Expired - Fee Related
- 1996-10-03 ES ES96936216T patent/ES2323818T3/es not_active Expired - Lifetime
- 1996-10-03 BR BR9610802A patent/BR9610802A/pt unknown
- 1996-10-03 EE EE9800105A patent/EE9800105A/xx unknown
- 1996-10-03 EP EP96936216A patent/EP0871487B1/de not_active Expired - Lifetime
- 1996-10-03 TR TR1998/00607T patent/TR199800607T1/xx unknown
- 1996-10-03 DE DE69637942T patent/DE69637942D1/de not_active Expired - Lifetime
- 1996-10-03 KR KR1020047011434A patent/KR100676792B1/ko not_active Expired - Fee Related
- 1996-10-03 CA CA002232865A patent/CA2232865A1/en not_active Abandoned
- 1996-10-03 SI SI9620116A patent/SI9620116A/sl unknown
- 1996-10-03 PL PL96325964A patent/PL187329B1/pl not_active IP Right Cessation
- 1996-10-03 CZ CZ98977A patent/CZ97798A3/cs unknown
- 1996-10-03 AU AU73922/96A patent/AU697539B2/en not_active Ceased
- 1996-10-03 RO RO98-00824A patent/RO120579B1/ro unknown
- 1996-10-03 AT AT96936216T patent/ATE432085T1/de not_active IP Right Cessation
- 1996-10-03 JP JP51449097A patent/JP3631496B2/ja not_active Expired - Fee Related
- 1996-10-03 NZ NZ321039A patent/NZ321039A/en unknown
- 1996-10-03 KR KR10-1998-0702286A patent/KR100514957B1/ko not_active Expired - Fee Related
1998
- 1998-03-26 IS IS4703A patent/IS4703A/is unknown
- 1998-03-26 NO NO981374A patent/NO981374L/no unknown
- 1998-04-02 LV LVP-98-63A patent/LV12085B/en unknown

Also Published As

Publication number	Publication date
EE9800105A (et)	1998-10-15
CZ97798A3 (cs)	1999-02-17
PL187329B1 (pl)	2004-06-30
WO1997012633A1 (en)	1997-04-10
JP3631496B2 (ja)	2005-03-23
KR19990063818A (ko)	1999-07-26
SK40898A3 (en)	1999-04-13
EP0871487B1 (de)	2009-05-27
LV12085A (lv)	1998-07-20
NZ321039A (en)	2001-03-30
SI9620116A (sl)	1999-08-31
KR100514957B1 (ko)	2005-11-25
BR9610802A (pt)	1999-07-13
ES2323818T3 (es)	2009-07-24
KR20040079421A (ko)	2004-09-14
LV12085B (en)	1998-09-20
NO981374L (no)	1998-06-03
JPH11513389A (ja)	1999-11-16
AU697539B2 (en)	1998-10-08
CN1229359A (zh)	1999-09-22
TR199800607T1 (xx)	1998-06-22
EP0871487A4 (de)	2004-09-01
CA2232865A1 (en)	1997-04-10
CN1172718C (zh)	2004-10-27
PL325964A1 (en)	1998-08-17
DE69637942D1 (de)	2009-07-09
NO981374D0 (no)	1998-03-26
EP0871487A1 (de)	1998-10-21
AU7392296A (en)	1997-04-28
IS4703A (is)	1998-03-26
KR100676792B1 (ko)	2007-02-02
EA199800272A1 (ru)	1998-10-29
RO120579B1 (ro)	2006-04-28

Legal Events

Date	Code	Title	Description
2009-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE432085T1 (de)	2009-06-15	Stimulationsfaktor für dendriten
NZ333607A (en)	2000-08-25	Method of stimulating the immune system by transfecting dendritic cells
IL114444A0 (en)	1995-11-27	Multi-stage cascade boosting vaccine
DK0633929T3 (da)	2004-06-28	Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
GR3036951T3 (en)	2002-01-31	Cells with multiple altered epitopes on a surface antigen for use in transplantation
ATE195875T1 (de)	2000-09-15	Spezifische modulationen des immunsystems
ATE389712T1 (de)	2008-04-15	Krebs immuntherapie mit semi-allogenen zellen
CY1110235T1 (el)	2015-01-14	Χρηση αλλογενετικων κυτταρικων γραμμων για τη φορτωση κυτταρων που εμφανιζουν αντιγονο για την προκληση ή εξαλειψη ανοσολογικων απαντησεων
NZ322910A (en)	2000-05-26	Tumour vaccine containing tumour cells, some with MHC-I-haplotype on cell surface to trigger immune response, and preparation of vaccine thereof
DK0843731T3 (da)	2008-06-09	Adenovirusvektorer til genterapi
NZ507829A (en)	2004-03-26	Vaccine adjuvants for immunotherapy of melanoma
ITRM920350A1 (it)	1993-11-11	Epitopi immunologicamente omologhi di hla e proteine del virus hiv.
DE50008756D1 (de)	2004-12-30	Peptid aus antigen muc-1 zur auslösung einer immunreaktion gegen tumorzellen
Schäkel et al.	2000	M-DC8+ leukocytes–a novel human dendritic cell population
DK1021196T3 (da)	2004-06-07	Anvendelse af en kemisk stabiliseret chloritoplösning til inhibering af en antigenspecifik immunreaktion
US4017361A (en)	1977-04-12	Process for obtaining continuous lines of tumoral cells in vitro
AU5573196A (en)	1996-11-18	A pluripotent vaccine against enveloped viruses
ATE374244T1 (de)	2007-10-15	Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
Warnatz et al.	1976	Studies on the specificity of in vitro induced lymphocytotoxicity to SV40-transformed fibroblasts
Bocchieri et al.	1982	Detection of autologous mixed lymphocyte reaction responding cells and their precursor frequency in NZB mice
Sofra et al.	2009	Antigen‐loaded ER microsomes from APC induce potent immune responses against viral infection
Fischer et al.	1985	Bone marrow macrophages induced to antigen presentation by lymphokines interact selectively with distinct T cells
Suciu-Foca et al.	1989	7.1-03 A new differentiation antigen, NDA5, involved in the amplification of primary and memory T cell responses
Harris et al.	1989	7.1-04 A new differentiation antigen NDA4 involved in the growth and functional maturation of T and of B lymphocytes
Faherty	1985	CLONAL ANALYSIS OF AUTOREACTIVE HELPER T CELLS.